China Medical System Holdings Limited (CMS) released its interim results for the six months ended 30 June 2026, highlighting double-digit top-line growth and intensified R&D investment.
Financial Performance • Turnover rose 12.5% year-on-year to RMB 4.50 billion; on a fully direct-sales basis revenue would have been RMB 5.34 billion, up 14.4%. • Gross profit increased 11.4% to RMB 3.22 billion, with gross margin easing 0.7 percentage point to 71.6%. • Net profit grew 4.3% to RMB 971.50 million; basic EPS advanced 4.7% to RMB 0.4075. • Cash and bank balances stood at RMB 2.57 billion; gearing ratio was 4.2%. • Interim dividend declared at RMB 0.1634 per share (payable 8 September 2026), 5.1% higher than last year. • About 6.40 million shares were repurchased for HKD 67.90 million and held as treasury stock.
Operational Highlights • Revenue from innovative and exclusive products jumped 19.7% to RMB 1.70 billion, accounting for 37.7% of turnover. • Skin Health segment sales surged 59.1% to RMB 792.53 million; Ophthalmology sales rose 32.0% to RMB 472.80 million (96.8% to RMB 704.70 million on a direct-sales basis). • Products affected by national volume-based procurement stabilised, delivering RMB 1.10 billion in sales, up 4.6%.
R&D and Pipeline • Total R&D investment nearly doubled to RMB 824.70 million, 18.3% of turnover. • Three innovative drugs approved in China: Silevimig Injection, Desidustat Tablets and Lumirix (ruxolitinib phosphate cream). • Five NDAs under review covering six indications, including Loberamisal for Injection and Comekibart Injection. • Three in-house candidates received IND clearances; a new collaboration with Denmark’s Pharmacosmos adds Monofer and Cosmofer intravenous iron therapies.
Segment Results • Integrated Pharmaceuticals: revenue RMB 3.71 billion, profit RMB 914.02 million. • Skin Health: revenue RMB 792.54 million, profit RMB 57.47 million.
Additional Developments • MSCI upgraded CMS’s ESG rating to AAA; inclusion in the S&P Global Sustainability Yearbook 2026. • Average trade receivables days improved to 78; inventory days fell to 124.
The board affirmed CMS’s commitment to innovation-driven growth and ongoing investment across its specialty areas, including cardiovascular-kidney-metabolic, CNS, gastroenterology, ophthalmology and skin health.
Comments